Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of NOXXON. NOXXON disavows any obligation to update or correct the information contained in these publications.

Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.
Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.
Sci Rep. 2018, 8(1), 1841.
read abstract on pubmed.gov

Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Oncotarget. 2017, 8(66), 109973-84.
read abstract on pubmed.gov

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M.
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib – dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Leukemia. 2017, 31, 997-1000.
read article on pubmed.gov

Deng L, Stafford JH, Liu SC, Chernikova SB, Merchant M, Recht L, Martin Brown J.
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Neoplasia. 2017, 19(1), 1-7.
read abstract on pubmed.gov

Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A.
Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade.
Cancer Immunol Res. 2017.
read article on aacrjournals.org

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Br J Haematol. 2017, 179(1), 36.
read abstract on pubmed.gov

Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
Clin Immunol. 2016.
read abstract on pubmed.gov

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Kruschinski A, Dümmler T, Riecke K, Ghia P, Caligaris-Cappio F, Gobbi M.
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia.

ASH
2014, San Francisco
Poster

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Zojer N, Riecke K, Kruschinski A, Dümmler T, Foa R, Greil R, Yakoub-Agha I, Engelhardt M.
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma.

ASH
2014, San Francisco
Poster

Zboralski D, Vater A, Kruschinski A.
Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated by Rituximab and Obinutuzumab.

ASH
2014, San Francisco
Poster

Roccaro et al.
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
Cell Reports. 2014, 9(1), 118-28.
read article on cell.com

Liu S-C, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D, Zöllner S, Kruschinski A, Klussmann S, Recht L, Brown JM.
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.

Neuro-Oncology.
2014, 16(1), 21-28.
read article on oxfordjournals.org

Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA.
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

Blood.
2014, 123(7), 1032-1039.
view abstract on hematologylibrary.org

Marasca R, Maffei R.
Comment on Hoellenriegel et al
NOX-A12: mobilizing CLL away from home.

Blood.
2014, 123(7), 952-953.
read comment on hematologylibrary.org

Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F.
Hematopoietic stem and progenitor cell mobilization in mouse and man by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.

Clinical Pharmacology and Therapeutics.
2013, 94(1), 150-7.
read article on nature.com

Zboralski D, Hoellenriegel J, Maasch C, Kruschinski A, Burger JA
Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer NOX-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 318
read ASH abstract on hematologylibrary.org

Gobbi M, Caligaris-Cappio F, Montillo M, Vauléon S, Zöllner S, Dümmler T, Kruschinski A, Fliegert F
Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer NOX-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4593logylibrary
read ASH abstract on hematologylibrary.org

Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT.
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2012, Vol. 186(9), 897-908.
view PubMed abstract on ncbi.nlm.nih.gov

Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.
Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease.
Am J Pathol. 2011, Vol. 179(1), 116-24.
view PubMed abstract on ncbi.nlm.nih.gov

Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.

Diabetologia 2009, Vol. 52(11), 2445-2454.
view PubMed abstract on ncbi.nlm.nih.gov